Medullary thyroid carcinoma associated with multiple myeloma: A case report

Seyyed Mohammadreza Mortazavizadeh, Yasaman Ayoughi, Fariba Binesh, Moein Karbalaeian

ABSTRACT

Introduction: The co-existence multiple myeloma (MM) and another cancer have been reported severally in literature, but medullary thyroid carcinoma (MTC) as a second cancer with multiple myeloma is an extremely rare case, to our knowledge, there are no prior reports of these concurrent cancers.

Case Report: A 54-year-old man was admitted with chief complain of bone pain, clinical investigation revealed, lytic bone lesions and infiltration of plasma cells in bone marrow and patient with diagnosis of multiple myeloma received chemotherapy, he was in partial remission, but nine months later a solitary nodule was founded in his thyroid, with high levels of calcitonin and fine needle aspiration (FNA) reported the medullary thyroid carcinoma, after total thyroidectomy which confirmed this cancer the patient recovered and now he is followed-up for these cancers.

Conclusion: Diagnosis of secondary cancer is important because: first to distinguish secondary malignancy from metastatic cancer and then try to investigate the etiology of this association.
Medullary thyroid carcinoma associated with multiple myeloma: A case report

Seyyed Mohammadreza Mortazavizadeh, Yasaman Ayoughi, Fariba Binesh, Moein Karbalaeian

ABSTRACT

Introduction: The co-existence multiple myeloma (MM) and another cancer have been reported severally in literature, but medullary thyroid carcinoma (MTC) as a second cancer with multiple myeloma is an extremely rare case, to our knowledge, there are no prior reports of these concurrent cancers. Case Report: A 54-year-old man was admitted with chief complain of bone pain, clinical investigation revealed, lytic bone lesions and infiltration of plasma cells in bone marrow and patient with diagnosis of multiple myeloma received chemotherapy, he was in partial remission, but nine months later a solitary nodule was founded in his thyroid, with high levels of calcitonin and fine needle aspiration (FNA) reported the medullary thyroid carcinoma, after total thyroidectomy which confirmed this cancer the patient recovered and now he is follow-up for these cancers. Conclusion: Diagnosis of secondary cancer is important because: first to distinguish secondary malignancy from metastatic cancer and then try to investigate the etiology of this association.

Keywords: Medullary thyroid cancer, Multiple Myeloma, Secondary malignancy, Thyroid carcinoma

INTRODUCTION

Multiple myeloma (MM) is a hematologic cancer which usually manifested by bone pain, hypercalcemia, anemia, lytic bone lesions and monoclonal gammopathy. The co-existence multiple myeloma and another cancer such as renal cell carcinoma, lung, gastric carcinoma, colon, prostate, breast, bladder, uterus, and liver have been reported severally in literature [1–5], but medullary thyroid carcinoma (MTC) as a second malignancy with multiple myeloma is an extremely rare case which seems has not been reported before, here we are presenting a case with these two types of cancer.
CASE REPORT

A 54-year-old male with diabetes history presented on 17th November 2013 with complaints of severe bone pain on his shoulder and vomiting. The physical examination was unremarkable but a primary photo X-ray in emergency room showed abnormal lytic lesions in the bone and pathologic fracture in clavicle (Figure 1), so he was referred to the oncologist with high suspicion for a malignancy, the primary laboratory investigation revealed ESR: 77 mm/h, the skull X-ray showed multiple punched out lesions (Figure 2).

And the whole body scan reported multiple irregular and abnormal uptake in anterior and posterior rib-skull-right shoulder and highly suggestive multiple bone metastasis (Figure 3) in the next laboratory investigation yielded the following findings: β₂-microglobulin: 9.9(1.1-2.4) mg/L, α₂: 17.6 (7.1-11.8) g/L, in his urine electrophoresis, Lambda light chain was 88 (5.9) mg/L, (detailed results laboratory tests are given in Table 1), the aspiration of bone marrow found 25% plasma cells which some were multiple nucleus and others looking plasma blast (detailed reports of bone marrow aspiration is given in Table 2) and biopsy of bone marrow reported that hematopoietic cells have been replaced by proliferation of plasma cells and finally with diagnosis of the multiple myeloma, chemotherapy was initiated for patient with the regimen of VAD (vincristine, Adriablastina, dexamethasone) and zometa.

After four cycles chemotherapy, once more bone marrow aspiration revealed incomplete response to cure with 15% plasma cells and evaluation of free lambda light chain was 124 (up to 5.9) mg/L so the chemotherapy changed and continued with velzomib, and once more bone marrow aspiration showed mild plasmacytosis 7% and the patient reached a partial remission, about after nine months later, the laboratory tests changed and ESR elevated for second time, during investigation we found a palpable solitary nodule in the thyroid of patient, the thyroid function test showed TSH: 2.6 mIU/L, T4: 8.5 μg/dL and T3: 142 ng/dL and ultrasonography of thyroid reported a well-defined hypoechoic solitary nodule in middle of right lobe of thyroid with numerous and small zones of calcification with no adenopathy in neck and suggested for fine needle aspiration (FNA) because it was suspicious for malignancy, in that time some differential diagnosis were made: metastasis of multiple myeloma to thyroid, or primary thyroid malignancy metastasis to bone and our first diagnosis of multiple myeloma could be rejected by this assumption and the last one diagnosis was thyroid malignancy as a secondary cancer. Therefore, the patient underwent FNA which reported medullary thyroid carcinoma with the laboratory test investigation of calcitonin: 268 ng/L, CEA: 78 μg/L, ESR: 63 mm/h and with these evidences the probability of metastatic of primary multiple myeloma ruled out. And with diagnosis of MTC, patient was referred to surgeon and after total thyroidectomy, the histopathology confirmed medullary thyroid carcinoma (Figure 4).

After surgery the patient was recovered and the laboratory tests return to nearly normal levels. The patient remained in good health and he is followed-up for these malignancies.

DISCUSSION

Second primary cancer is one of the effective prognostic factors among cancer survivors and it is estimated to be the sixth most common form of malignancy in the world [6], although secondary solid neoplasms in patients with multiple myeloma are rare, but some studies have reported the increasing risk of that. In a study by Stegeman et al., multiple myeloma and solid tumor co-existence was found to be 3% [7] and Kyle at al. reported that, in 1027 patients diagnosed with multiple myeloma, the proportion of secondary hematologic malignity was 0.7% and the proportion secondary solid malignancy was 1.9% [8]. As we mentioned earlier, malignancies synchronized with
multiple myeloma have been reported before [1–5]. But it was not included medullary thyroid carcinoma which occurs extremely rare, to our knowledge there are no prior reports of this case. The etiology of this correlation in our case is not clear but according to some hypothesis, secondary malignancies associated with MM can be because of behaviors (such as smoking, harmful levels of alcohol consumption and poor diet), inherited susceptibilities and/or the medical treatment.

Table 1: Laboratory results of the patients

<table>
<thead>
<tr>
<th>Protein fractions (g/L)</th>
<th>Protein fractions (g/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cell</td>
<td>8600 mm³</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>13.9 g/dL</td>
</tr>
<tr>
<td>Platelet</td>
<td>282000 mm³</td>
</tr>
<tr>
<td>ESR</td>
<td>77 mm/h</td>
</tr>
<tr>
<td>BUN</td>
<td>10 mg/dL</td>
</tr>
<tr>
<td>Creatinine</td>
<td>1 mg/dL</td>
</tr>
<tr>
<td>LDH</td>
<td>408 U/L</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>279 U/L</td>
</tr>
<tr>
<td>SGPT</td>
<td>15 U/L</td>
</tr>
<tr>
<td>SGOT</td>
<td>20 U/L</td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td>1.1 mg/dL</td>
</tr>
<tr>
<td>IgG</td>
<td>1577 mg/dL</td>
</tr>
<tr>
<td>IgM</td>
<td>81.6 mg/dL</td>
</tr>
<tr>
<td>IgA</td>
<td>108 mg/dL</td>
</tr>
</tbody>
</table>

that cancer survivors have received [9–10]. Further investigations would be done in order to understand of whether this secondary malignancy is only accidental or whether there is any cause and effect relationship, another point of this case is about the differential diagnosis of thyroid nodule which was discovered some months after diagnosis multiple myeloma that could be mistaken by metastasis of multiple myeloma to thyroid gland which has been reported severally [11–13] or the primary cancer was MTC which could metastasis to bone and mimicked the multiple myeloma and it could change the way of treatment. But pathology samples and the elevation of laboratory markers such as calcitonin level excluded it and responding to cure and remission after total thyroidectomy, ruled out the second suspicious diagnosis. And another things which should be kept in mind in these kind of cases, try to investigate and pay attention to the new signs and symptoms which set during disease and may not be related to the primary cancer or complications of it, and another associated disease should be considered even if it is too unusual. In this case, patient reached to remission after chemotherapy but once more elevated ESR caused to investigate more.

**CONCLUSION**

A rare correlation between multiple myeloma and medullary thyroid carcinoma case is reported, diagnosis of secondary cancer is important because: first: to distinguish secondary malignancy from metastatic cancer then try to investigate the etiology of this association and finally to determine to choose the best treatment because of its good prognosis.

**Table 2: Bone marrow biopsy results**

<table>
<thead>
<tr>
<th>Cell count in bone marrow (%)</th>
<th>First time (BMA) Before starting chemotherapy</th>
<th>Second time(BMA) After four cycle chemotherapy</th>
<th>Third time (BMA) After changing chemotherapy to velzomib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blast</td>
<td>4</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Promyelocyte</td>
<td>7</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Metamyelocyte</td>
<td>8</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Myelocyte</td>
<td>6</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>Band cell</td>
<td>12</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Neutrophil</td>
<td>11</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>Eosinophil</td>
<td>2</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Plasma cell</td>
<td>25</td>
<td>15</td>
<td>7</td>
</tr>
<tr>
<td>Erythroid cells different</td>
<td>14 Megakaryocytes sporadically seen</td>
<td>46 Megakaryocytes sporadically seen</td>
<td>35 Megakaryocytes seen enough</td>
</tr>
<tr>
<td>Diagnosis:</td>
<td>Plasma cell myeloma</td>
<td>Diagnosis: Incomplete response</td>
<td>Diagnosis: Mild plasmacytosis</td>
</tr>
</tbody>
</table>

**Author Contributions**

Seyyed Mohammad Reza Mortazavizadeh – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Yasaman Ayoughi – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Fariba Binesh – Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Moein Karbalaeian – Acquisition of data, or analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

**Guarantor**
The corresponding author is the guarantor of submission.

**Conflict of Interest**
Authors declare no conflict of interest.

**Copyright**
© 2016 Seyyed Mohammad Reza Mortazavizadeh et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
REFERENCES

Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.